Literature DB >> 3488219

Detection of cytotoxicity of freshly obtained lymphocytes and of lymphocytes activated with recombinant interleukin II (rIL-2) against lung cancer cell lines by human tumor clonogenic assay (HTCA).

J Fujita, N Saijo, Y Sasaki, H Futami, J Ishihara, H Takahashi, A Hoshi, A W Hamburger.   

Abstract

The cytotoxicity of freshly obtained human peripheral blood lymphocytes and lymphocytes activated with human recombinant interleukin II (rIL-2) was evaluated against lung cancer cell lines by the human tumor clonogenic assay. Colony formation of all human lung cancer cell lines, PC-1, 3, 6, 7, 9, 13 and 14 were suppressed by lymphocytes activated with 100 units/ml of human rIL-2 for 72 hr. However, the degree of the suppression of colony formation by lymphocytes activated with rIL-2 was different for each cell line. The per cent inhibition of colony formation obtained by HTCA correlated well with the per cent cytolysis obtained by 51Cr-release assay for all cell lines. HTCA provides a very useful tool for the detection of cytotoxicity of lymphocytes against clonogenic tumor cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488219     DOI: 10.1016/0277-5379(86)90111-2

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  3 in total

1.  Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.

Authors:  S Sone; E Kunishige; F Fawzy; H Yanagawa; A Nii; K Maeda; S Atagi; Y Heike; Y Nishioka; K Mizuno
Journal:  Jpn J Cancer Res       Date:  1991-06

2.  Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs.

Authors:  A Ohtsu; Y Sasaki; T Tamura; Y Fujiwara; Y Ohe; K Minato; K Nakagawa; M Bungo; N Saijo
Journal:  Jpn J Cancer Res       Date:  1989-03

3.  Three schedules of recombinant human interleukin-2 in the treatment of malignancy: side effects and immunologic effects in relation to serum level.

Authors:  T Sano; N Saijo; Y Sasaki; T Shinkai; K Eguchi; T Tamura; M Sakurai; H Takahashi; H Nakano; K Nakagawa
Journal:  Jpn J Cancer Res       Date:  1988-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.